Evidence map›Paper›PMID 36458557›Full record

ArticleTurkish journal of haematology : official journal of Turkish Society of Haematology2023

Circulating CD133+/–CD34– Have Increased c-

İldeniz Uslu Bıçak, Berkay Tokcan, Akif Selim Yavuz, Selçuk Sözer Tokdemir

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Turkish journal of haematology : official journal of Turkish Society of Haematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

İldeniz Uslu Bıçakİstanbul University Aziz Sancar Institute of Experimental Medicine, Department of Genetics, İstanbul, TürkiyeORCID 0000-0002-4210-7290
Berkay Tokcanİstanbul University Aziz Sancar Institute of Experimental Medicine, Department of Genetics, İstanbul, TürkiyeORCID 0000-0001-9034-8841
Akif Selim Yavuzİstanbul University Faculty of Medicine, Department of Internal Medicine, Division of Hematology, İstanbul, TürkiyeORCID 0000-0001-9049-4654
Selçuk Sözer Tokdemirİstanbul University Aziz Sancar Institute of Experimental Medicine, Department of Genetics, İstanbul, TürkiyeORCID 0000-0002-5035-4048
Istanbul University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Myeloproliferative neoplasms (MPNs) are hematopoietic stem cell (HSC)-originated diseases with clonal myeloproliferation. The constitutive activation of the JAK/STAT pathway is frequently detected in patients with Philadelphia chromosome-negative (Ph–) MPNs with an acquired Materials and Methods: Mononuclear cells (MNCs) of Ph– MPNs were fluorochrome-labeled in situ with wild-type (wt) Results: The mRNA-labeled gold nanoparticle-treated MNCs were determined to have the highest ratio of c- Conclusion: This is the first study of circulating CD133

Indexed as

Metal NanoparticlesMyeloproliferative DisordersNeoplasmsAntigens, CD34GoldHumansJanus Kinase 2Janus KinasesRNA, MessengerSignal TransductionSTAT Transcription FactorsAntigens, CD34GoldJanus Kinase 2Janus KinasesRNA, MessengerSTAT Transcription FactorsCD133CD34c-MYCEndothelialprogenitor cellGold-nanoflareHematopoieticstem cellsJAK2V617FMyeloproliferative neoplasms

Identifiers

PMID36458557
PMCPMC9979741
OpenAlexW4310603285

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.